Ergoresearch Inc. Reports Record Sales and Earnings for Fiscal 2009 - Sales up 24.9% to $6 633 049 and Earning Before Income Tax and Non-Controlling Interest of $738,353

MONTREAL, QUEBEC--(Marketwire - October 28, 2010) - Ergoresearch ltd (TSX VENTURE: ERG)

 -- Revenues for the period increased by 24.9% to $6,633,049, compared to $5,308,708 in 2009. -- Income before tax and non-controlling interest significantly increased to $738,353, an increase of 70.3%, compared to $433,487 for the same period last year. -- Cash flow generated from operating activities increased by 11.1% to $957,764, compared to $862,242 for the same period last year. 

All amounts in Canadian dollars unless otherwise stated.

Ergoresearch ltd (“Ergoresearch” or the “Corporation”) (TSX VENTURE: ERG) announced today its results for the fourth quarter and the 2010 fiscal year ended June 30, 2010. During the year, Ergoresearch recorded unprecedented sales and a strong growth in Income before income tax and non- controlling interest and cash generated from operating activities.

During the fiscal year ended June 30, 2010, the Corporation’s sales reached $6 633 049, representing a 24,9% increase compared to the 2009 fiscal year end results then at $5 308 708. The Corporation recorded yet another profitable year, the fifth consecutive one, with an Income before income tax and non-controlling interest of $738 353 for the 2010 fiscal year, significantly better than the Income before income tax and non-controlling interest of $433 487 recorded in fiscal 2009. For financial year 2010, the Corporation used all its deferred losses and registered $283,469 in tax expense.

“We are pleased with the financial results of the fiscal year 2010 and enthusiastic about recent accomplishments and future projects. The management team will continue its rigorous work in order to further evolve its immediate projects and identify acquisitions that will create value for the Corporation’s shareholders. We are actively preparing for the next expansion phase with, among others, the development of new foot orthotics products and “Web-based” clinical management software. It is important to outline the efforts made by our employees, officers and directors of the Corporation throughout the year. Their work, orchestrated around common objectives, allow the Corporation to target the highest summits. I am extremely grateful to them.” stated Sylvain Boucher, President and CEO of Ergoresearch Ltd.

Forward-looking statements

Certain statements in this Press Release contain forward-looking statements and information that may entail certain risks related to uncertainties. Such statements are based on management’s expectations and no assurance can be given that potential future results or circumstances described in the forward looking statements will be achieved or will occur. Such risks factors include, but are not limited to, those related to the Corporation’s ability to finance its activities, competition, fluctuations in operating results, the impact of general economics, industry and market conditions, the ability to recruit and retain qualified employees, fluctuations in cash flow, expectations regarding market demand for particular products and the dependence on new product development.

The reader should not give great importance to forward-looking statements as (i) the results may differ from conclusions, predictions or projections contained in such forward-looking statements; and (ii) certain important factors or hypothesis taken into account in reaching conclusions or the preparation of a projection or prediction may prove to be incorrect in fact.

Management disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Ergoresearch Ltd (www.ergorecherche.com) through its subsidiaries (www.cliniquedupiedequilibre.com ) and Orthoconcept (2008) Inc. (www.orthoconcept.com ) is a leading general and foot orthotics manufacturer as well as being on the leading edge of durable medical equipment development in the orthopaedic industry (www.ErgoIntel.com). The Corporation pursues its goal to become an international leader in technologies and solutions aimed at improving health and well-being.

The TSX Venture exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.